Jakub Radocha

Dr. Jakub Radocha

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
TJTomas Jelinek
Tomas Jelinek
RBRenata Bezdekova
Renata Bezdekova
DZDavid Zihala
David Zihala
TSTereza Sevcikova
Tereza Sevcikova
ASAnjana Anilkumar Sithara
Anjana Anilkumar Sithara
RHRoman Hajek
Roman Hajek
PURPOSE: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. METHODS: We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. RESULTS: Newly diagnosed transplant-ineligible patients with MM with 2%-20% CTCs had significantly shorter progression-free survival (3.1 v 15.6 months; P < .001) and overall survival (14.6 v 33.6 months; P = .023) than patients with < 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. CONCLUSION: Our study uncovers that ≥ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.

10 July 2021 in Leukemia
Verified
Journal Article
Closed access
PDF file
TJTomas Jelinek
Tomas Jelinek
TSTereza Sevcikova
Tereza Sevcikova
DZDavid Zihala
David Zihala
TPTereza Popkova
Tereza Popkova
VKVeronika Kapustova
Veronika Kapustova
RHRoman Hajek
Roman Hajek

29 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JRJakub Radocha
Jakub Radocha
NDNiels W.C.J. Van De Donk
Niels W.C.J. Van De Donk
Katja WeiselKatja Weisel
Katja Weisel
Multiple myeloma is the second most common hematologic malignancy. Current treatment strategies are mainly based on immunomodulatory drugs, proteasome inhibitors or combination of both. Novel agents added to these backbone treatments represent a promising strategy in treatment of newly diagnosed as well as relapsed and refractory multiple myeloma patients. In this respect, the incorporation of monoclonal antibodies into standard-of-care regimens markedly improved prognosis of myeloma patients during the last years. More specifically, monoclonal anti-CD38 antibodies, daratumumab and isatuximab, have been implemented into treatment strategies from first-line treatment to refractory disease. In addition, the monoclonal anti-SLAM-F7 antibody elotuzumab in combination with immunomodulatory drugs has improved the clinical outcomes of patients with relapsed/refractory disease. Belantamab mafodotin is the first approved antibody drug conjugate directed against B cell maturation antigen and is currently used as a monotherapy for patients with advanced disease. This review focuses on clinical efficacy and safety of monoclonal antibodies as well as antibody drug conjugates in multiple myeloma.

14 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJiří Minařík
Jiří Minařík
PPPetr Pavlicek
Petr Pavlicek
LPLudek Pour
Ludek Pour
TPTomas Pika
Tomas Pika
VMVladimir Maisnar
Vladimir Maisnar
FGfor the Czech Myeloma Group
for the Czech Myeloma Group
Subcutaneous (SC) application of bortezomib has been recently introduced as a new application route in multiple myeloma (MM) patients. We performed an analysis to compare the outcomes of bortezomib-based therapy in multiple myeloma (MM) patients treated using either intravenous (IV) or subcutaneous (SC) route of administration. During January 2012 through December 2013, we performed a retrospective analysis of 446 patients with MM treated with bortezomib-based regimens (either once weekly – 63% or twice weekly – 27%) in both, the first line setting, and in relapse, with separate analysis of patients undergoing autologous stem cell transplantation. We assessed the response rates and toxicity profiles in both, IV and SC route of bortezomib administration. The response rates in both IV and SC arm were similar with overall response rate 71.7% vs 70.7%, complete remissions in 13.9% vs 8.6%, very good partial remissions in 30.8% vs 34.5% and partial remissions in 27% vs 27.6%. The most frequent grade ≥3 toxicities were anemia, thrombocytopenia and neutropenia, with no significant differences between IV and SC group. There were no significant differences in the rate of peripheral neuropathy (PN). PN of any grade was present in 48% in the IV arm and in 41% in the SC arm. PN grade ≥2 was present in 20% vs 18% and PN grade ≥3 was present in 6% vs 4%. We conclude that subcutaneous application of bortezomib has similar therapeutic outcomes and toxicity profile as intravenous route of application. In our cohort there was no difference in the incidence of PN, suggesting that PN is dose dependent and might be reduced by lower intensity schemes rather than by the route of administration.

23 July 2019 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
IAIrit Avivi
Irit Avivi
YCYael Chava Cohen
Yael Chava Cohen
ASAnna Suska
Anna Suska
TSTamir Shragai
Tamir Shragai
GMGabor Mikala
Gabor Mikala
Artur JurczyszynArtur Jurczyszyn
Artur Jurczyszyn

18 February 2020 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
SGSarah Goldman‐Mazur
Sarah Goldman‐Mazur
Artur JurczyszynArtur Jurczyszyn
Artur Jurczyszyn
JCJorge J Castillo
Jorge J Castillo
AWAnna Waszczuk-Gajda
Anna Waszczuk-Gajda
NGNorbert Grząśko
Norbert Grząśko
DVDavid H. Vesole
David H. Vesole